Gilead Oncology Franchise Adding To Growth Scenario
luismmolina/iStock via Getty Images
Gilead Sciences (GILD) had revenue of $6.22 billion in Q2 2021, up 21% y/y. Nevertheless the company stock does not sport the high P/E (price-to-earnings) ratio that is typical of high-growth stocks. This low stock price…
